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Background
Migraine and epilepsy are chronic disorders, often
comorbid, characterized by transient and recurrent neu-
rological disturbances. Sharing pathophysiologic and
clinical features, both epilepsy and migraine benefit
from antiepileptic drugs (AEDs) treatment. However,
despite their overlapping, peculiar differences regarding
reported adverse events (AEs) of AEDs seem to emerge
in clinical practice. In particular, tolerability and fre-
quency of AEs might depend on the condition from
which the patient suffers. Therefore, we interviewed
patients treated with AEDs for epilepsy, migraine, and
both, in order to compare AEs distribution of frequency
among the three groups.
Materials and methods
We collected AEs of some AEDs - valproic acid (VPA),
topiramate (TPM), lamotrigine (LTG) - widely used in
prophylactic therapy of migraine, in epilepsy as well as
in epileptic migraineurs. All AEs were gathered through
the Liverpool Adverse Events Profile (LAEP) [1].
Results
Three hundred and thirty-five patients were recruited:
142 suffered from epilepsy (group A), 131 from head-
ache (group B), 62 from both (group C). Mean age was
44.5 in group A, 45.0 in B, 40.5 in C. AEs were signifi-
cantly more reported in group B (69.5%) and under
TPM treatment (71%). The most prescribed AED for
group B was TPM, which was more commonly referred
to cause paresthesias (68%) and language disorders
(42%) among this group than in the other two.
Complaints of weight gain were common with VPA in
all three groups, with higher frequencies among group
B and C. Memory impairment induced by AEDs was
reported more frequently for TPM in all three groups,
while maximal incidence was reported for VPA and
TPM, respectively in group B (5%) and C (9%). Overall,
migraineurs were more likely to drop out of treatment
(46%) than epileptic patients (29.6%) and patients with
epilepsy and migraine (41.9%).
Discussion and conclusions
Our data confirm the extensive safety and effectiveness
of AEDs in clinical practice, and point to patient’s toler-
ability of AEs as pivotal for a successful treatment [2].
We emphasize the higher prevalence of AEs due to
AEDs in migraineurs, suggesting a peculiar susceptibility
of their condition to experience AEs. This finding,
which emerges despite the average higher dosage of
AED used for epilepsy, remains actually unexplained.
Our results might be intriguingly considered as a clinical
implication of central sensitization mechanisms or, not
less intriguingly, they might represent the result of an
abnormal network plasticity producing microstructural
changes in migraine-affected brain [3].
Written informed consent to publication was obtained
from the patient(s).
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